Allogene Therapeutics ALLO Total Operating Expenses
Total Operating Expenses at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's total operating expenses?
- Allogene Therapeutics (ALLO) reported total operating expenses of $46.09M in Q1 2026.
- How has Allogene Therapeutics's total operating expenses changed year-over-year?
- Allogene Therapeutics's total operating expenses decreased by 29.3% year-over-year, from $65.19M to $46.09M.
- What is the long-term trend for Allogene Therapeutics's total operating expenses?
- Over 4 years (2021 to 2025), Allogene Therapeutics's total operating expenses has grown at a -8.2% compound annual growth rate (CAGR), from $294.28M to $209.32M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.